Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952210 | 0.93 | AHR (0.51) | PLA2G2ALTA4HNR5A1CA1CA2 | |
| SCHEMBL3790617 | 0.90 | LTA4H (0.41) | PLA2G2ALTA4HBLMCA1CA2 | |
| SCHEMBL29953152 | 0.89 | TP53 (0.41) | PLA2G2ALTA4HNR5A1CA1CA2 | |
| SCHEMBL29951255 | 0.88 | MAPT (0.42) | PLA2G2ALTA4HNR5A1CA1CA2 | |
| SCHEMBL3792825 | 0.88 | TSHR (0.45) | PLA2G2ALTA4HNR5A1CA1CA2 | |
| SCHEMBL16065807 | 0.88 | LTA4H (0.39) | PLA2G2ALTA4HNR5A1CA1CA2 | |
| SCHEMBL16687425 | 0.88 | LTA4H (0.39) | PLA2G2ALTA4HNR5A1BLMCA1 | |
| SCHEMBL29955738 | 0.84 | FAAH (0.42) | PLA2G2ALTA4HNR5A1 | |
| SCHEMBL17236433 | 0.84 | SMN1; SMN2 (0.42) | PLA2G2ALTA4HNR5A1AHR | |
| SCHEMBL29953751 | 0.83 | ENPP2 (0.46) | PLA2G2ALTA4HCA1CA2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567526-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | PLA2G2A 3804/4885LTA4H 2263/4885NR5A1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.